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Risk of malignancy with long-term immunosuppression in renal
transplant recipients.
Background. Improvements in immunosuppressive regimens
have significantly enhanced patient and graft survival in renal
transplant recipients. However, susceptibility to neoplastic dis-
orders is increased as a consequence of prolonged immuno-
suppression. Available data pertaining to cancer risks in renal
transplant recipients have been inconsistent, and much of it is
derived from international studies, which may not be truly rep-
resentative of the United States population.
Methods. We studied a total of 1979 transplants performed
in 1739 patients from a single center in the United States with
a mean follow-up of 6.1 years, and a total of 9852 person-years’
follow-up.
Results. The mean age at the time of diagnosis of cancer was
50 years, and the mean interval between transplant and diag-
nosis of cancer was 95 months. Older patients receiving a trans-
plant had a significantly higher risk for developing cancer as
opposed to younger patients (RR 6.2 for >60 years compared
with <40 years). When compared with the general population
using data from the Surveillance, Epidemiology and End Re-
sults (SEER) registry, the overall risk for nonskin malignan-
cies was modestly increased in our transplant recipients, with
a standardized incidence ratio (SIR) of 1.4 (P = 0.01). When
stratified by age groups, younger age at transplant (<40 years)
had the highest SIR, at 2.3 (P < 0.001). Similarly, duration post-
transplant >10 years had an SIR of 2.4 (P < 0.001).
Conclusion. We believe that this study is representative of
the United States’ renal transplant population, and highlights
the need for reduced immunosuppression in the long-term and
increased vigilance for cancers in younger patients receiving
renal transplantation.
Improvements in immunosuppressive regimens and
general care of the renal transplant recipient have led to
Key words: kidney transplantation, imunosuppression, post-transplant
neoplasms, cancer risk.
Received for publication September 9, 2003
and in revised form November 18, 2003
Accepted for publication January 23, 2004
C© 2004 by the International Society of Nephrology
significantly enhanced graft survival [1]. Despite the sub-
stantial benefits to mortality [2] and quality of life [3], the
result is longer exposure to immunosuppressive agents.
In addition to infections, this has been associated with
an increased risk of a variety of malignancies [4]. Many
appear to be associated with viral infection [5], such as
lymphomas (Epstein-Barr virus), cervical cancer (human
papilloma virus), and Kaposi’s sarcoma (human herpes
virus 8). Others, such as acquired cystic disease and sub-
sequent renal cell cancers [6], may be related to factors
associated with a preceding period of uremia, or more
generally, to a state of poor immune surveillance result-
ing from potent immunosuppressive medications [7].
One of the major repositories of information on ma-
lignancy after renal transplantation is from the very large
Cincinnati Transplant Tumor Registry (CTTR), which
represents a worldwide collection of cases [8]. However,
it does not include information on person-years of follow-
up, and therefore, cannot provide true estimates of cancer
risk based on incidence. While a number of single-center
and other registry studies have been published trying to
address this limitation, few had long periods of follow-
up or attempted to compare cancer risk with the general
population [9–18]. Furthermore, most studies are inter-
nationally based, and therefore may not be representa-
tive of the United States (U.S.) population because it is
known that the frequency and type of malignancies vary
significantly depending on the population studied [5, 8].
We studied a large group of renal transplant recipients
from a single center in the U.S. over a 35-year time span
to determine the incidence of malignancy compared with
the general population.
METHODS
Patient population
This study was a retrospective review of data col-
lected contemporaneously on all patients undergoing re-
nal transplantation at the University of Texas Medical
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Branch between July 1967 and May 2002. Although pa-
tients could receive transplant follow-up elsewhere, con-
tact was usually maintained with the study center on at
least an annual basis. Given the long period of study,
immunosuppressive regimens employed varied consid-
erably. Before 1984, the regimen primarily included dual
therapy with azathioprine and prednisone. Since 1984,
triple therapy with cyclosporine, azathioprine, and pred-
nisone has been most commonly used. In 1997, mycophe-
nolate mofetil replaced azathioprine as the third agent.
Tacrolimus was introduced in 1996, and has been increas-
ingly used in place of cyclosporine. Antibody agents have
been used as induction therapy in patients deemed to
be at high immunologic risk, and for delayed graft func-
tion. Rejection episodes were initially treated with pulse
methylprednisolone. Steroid-resistant, or severe rejec-
tion, episodes were treated with the monoclonal anti-
body OKT3 or polyclonal antithymocyte globulin (ATG).
Equine ATG was used until 1999, when it was replaced
by a rabbit preparation. Monoclonal antibodies directed
against the interleukin (IL)-2 receptor have also been
used for induction since 1999. With the various regimens,
1-year graft survivals for primary cadaveric transplants
have been 42%, 78%, and 91% for the periods before
1980, 1984 to 1989, and 1996 to 1998, respectively.
The study protocol was approved by the local Institu-
tional Review Board of the University of Texas Medical
Branch.
Data collection
Information for the study population was primarily ob-
tained from a computerized database maintained at the
study center on all transplant patients. Data collected for
this study included demographics such as age, gender, and
race, as well as information on the etiology of end-stage
renal disease (ESRD), donor source (living or cadaveric),
occurrence of neoplasm, date of transplant, graft, and
patient survival. For patients identified as having malig-
nancy, medical records, when available, were reviewed to
confirm the histology and date of diagnosis.
General population data on the incidence of malig-
nancy were obtained from the Surveillance, Epidemiol-
ogy and End-Results (SEER) registry [19]. The SEER
program is sponsored by the National Cancer Institute
and consists of a group of population-based tumor reg-
istries encompassing 11 states and covering approxi-
mately 14% of the U.S. population in its most recent form.
Of note, it excludes nonmelanoma skin cancer cases, and
current data spans from 1973 to 1999.
Statistical analysis
For purposes of the analyses and defining years of
follow-up, patients were censored at the time of death,
return to dialysis, diagnosis of malignancy, or at last time
of contact with the study center. Kaplan-Meier curves
were generated to estimate the cumulative probability of
malignancy-free graft survival. Means were calculated ±
standard deviation (SD).
To examine risk factors for the development of malig-
nancy in renal transplantation, multivariable regression
was performed using the Cox proportional hazards tech-
nique, with time to malignancy as the dependent variable.
Potential risk factors entered as independent variables in
the model were: age at transplant, race, transplant num-
ber, donor source, transplant year, and cause of ESRD.
For transplant year, a cut-off of 1984 was used because this
roughly separates the eras with and without calcineurin
inhibitor use. Relative risks with 95% confidence inter-
vals (CIs) were estimated for each risk factor. A P value
< 0.05 was considered significant. A second model was
created excluding nonmelanoma skin cancer cases to al-
low for comparability with the SEER general population
data analyses.
To estimate risk compared with the general popula-
tion, standardized incidence ratios (SIR) were calculated
for nonskin cancers based on observed compared with
expected numbers generated by multiplying the person-
years at risk by the appropriate sex-, race-, age-, and
calendar year–specific incidence rates obtained from pub-
licly available SEER data [20]. Cancer cases occurring be-
fore 1973 or after 1999 were attributed to the years 1973
and 1999, respectively. SIRs were also calculated for a va-
riety of strata, including age, race, selected sites of cancer,
donor source, transplant number, transplant year, dura-
tion of post-transplant, and cause of ESRD. The majority
of patients listed as Hispanic in the study center were
Mexican-American. The SIR for Hispanic race was deter-
mined using the term “White Hispanic” in the SEER data
and calculated only for cases since 1992, when the desig-
nation was introduced. Cases with incomplete follow-up
data were excluded from analysis. A 95% CI was gener-
ated for each SIR assuming a Poisson distribution for the
observed number of cases. A standard P value < 0.05 was
used for statistical significance. However, given the pos-
sibility of chance findings with multiple testing, a more
conservative significance level was also calculated using
the Bonferroni adjustment.
All analyses were performed using SAS (version 8,
Cary, NC, USA).
RESULTS
A total of 1979 transplants were performed in 1739
patients during the study period. This resulted in a to-
tal of 9852 person-years, with a mean follow-up of 6.1
years. Twenty-one percent of patients were followed for
more than 10 years’ post-transplantation, with the longest
follow-up being 30.3 years. Clinical and demographic
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Table 1. Patient and transplant characteristics
Cancer All transplants
Patient characteristic
Total patients 92 1739
Gender
Female 32 (34.8%) 687 (39.5%)
Male 60 (65.2%) 1052 (60.5%)
Race
Caucasian 53 (57.6%) 886 (50.9%)
African American 18 (19.6%) 376 (21.6%)
Hispanic 21 (22.8%) 449 (25.8%)
Others 0 28 (1.6%)
Cause of ESRD
DM 11 (12.0%) 362 (20.8%)
HTN 25 (27.2%) 315 (18.1%)
Glomerulonephritis 19 (20.7%) 309 (17.8%)
Miscellaneousa 37 (40.2%) 753 (43.3%)
Transplant characteristics
Total transplants 92 1979
Age at transplant years
<40 34 (37.0%) 1102 (55.6%)
40 to 59 48 (52.2%) 749 (37.9%)
≥60 10 (10.9%) 128 (6.5%)
Mean age at transplant 43.5 ± 13.5 36.4± 15.8
(years) ± SD
Number of transplants
1 76 (82.6%) 1739 (87.9%)
2 14 (15.2%) 213 (10.8%)
≥3 2 (2.2%) 27 (1.4%)
Donor source
Cadaveric 76 (82.6%) 1504 (76.0%)
Living related 14 (15.2%) 447 (22.6%)
Living unrelated 2 (2.2%) 28 (1.4%)
Transplant year
<1984 26 (28.3%) 520 (26.3%)
≥1984 66 (71.7%) 1459 (73.7%)
Abbreviations are: DM, diabetes mellitus; HTN, hypertension.
aIncluding renal dysplasia/agenesis, Alport’s disease, chronic pyelonephritis,
autosomal-dominant polycystic kidney disease, and etiology unknown.
characteristics of patients and transplants with and
without cancer is shown in Table 1. Most patients were
male, had a cadaveric donor, and were transplanted af-
ter 1984. Patients were racially diverse, with roughly
half being Caucasian, and the remainder divided be-
tween African-American and Hispanic groups. The dis-
tributions for most characteristics were generally similar
between patients with and without cancer, with the ex-
ception of age. Patients with cancer appeared to be older
at the time of transplant, with a mean age of 43.5 years
compared with 36.4 years for those without cancer.
A total of 92 cancers were identified, with a mean
time between transplant and diagnosis of 95 ± 71 months
(range 1.3 to 325). The mean age at time of diagnosis
was 50 ± 12 years. Fifty-four (59%) cases received an-
tibody induction. Table 2 lists the types of malignancy
observed. Skin cancer was most common, representing
40% of the neoplasms diagnosed. The next most com-
mon sites were gastrointestinal (13%), urologic (11%),
and lymphomas (9%). Figure 1 shows a Kaplan-Meier
curve of malignancy-free survival. The long-term cumu-
lative incidence was 19% for nonmelanoma skin cancer,
Table 2. Types of malignancy
Category Type Frequency
Skin Squamous cell carcinoma 18
Basal cell carcinoma 8
Both basal and squamous 7
Melanoma 2
Unspecified 2
Total 37
Gastrointestinal Colorectal 6
Esophageal 3
Cholangiocarcinoma 1
Hepatoblastoma 1
Hepatocellular carcinoma 1
Total 12
Urologic Renal cell carcinoma 6
Transitional cell carcinoma 3
Wilm’s tumor 1
Total 10
Genital Cervical carcinoma 2
Vulvar carcinoma 1
Total 3
Breast Total 4
Lung Total 4
Lymphomas Total 8
Kaposi’s sarcoma Total 2
Prostate Total 2
Thyroid Total 1
Othersa Total 9
Total Total 92
aUnknown primary (3), sarcoma (2), unspecified type (1), oligodendroglioma
(1), mucoepidermoid carcinoma (1), myelofibrosis (1).
and 17% for other cancers, yielding a total incidence of
malignancy of 36% at 25 years.
Table 3 presents two multivariable models examining
risk factors for development of malignancy after renal
transplantation, both including and excluding non-
melanoma skin cancer. For both models, the only factor
to achieve statistical significance was age at transplan-
tation. This demonstrated increasing risk of malignancy
with older age.
Table 4 exhibits standardized incidence ratios com-
paring the renal transplant cohort with the general
population for the different demographic and clini-
cal characteristics for only those patients with nonskin
cancers. Using a P value < 0.05 as a cut-off, the SIR for
all cancers was significant at 1.4. For individual sites of
malignancy, breast and lung cancer appeared less fre-
quently in the transplant population, with a SIR of 0.7
each, while lymphomas, renal cancers, and colorectal can-
cers were more common in transplanted patients, with
SIRs of 4.9, 7.2, and 1.5, respectively. Only the youngest
age category of less than 40 years at the time of transplan-
tation had a significantly elevated SIR at 2.3. Hispanic
and African American race, two or more transplants, liv-
ing donor, hypertension as cause of ESRD, and duration
of post-transplant >10 years all had significantly elevated
SIRs. Using the more conservative Bonferroni corrected
P value of 0.002, only age <40 years, lymphomas, renal
cell cancers, two or more transplant number, and post-
transplant duration >10 years remained significant.
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Fig. 1. Kaplan-Meier curve of malignancy-
free survival.
DISCUSSION
This is the first single-center study from a U.S.-
based renal transplant program that provides cancer risk
estimates in comparison to the general population. It
not only confirms, but extends, the results of previous
studies addressing the issue of malignancy after renal
transplantation.
The overall risk of cancer in renal transplant recipients
in our study was only slightly increased, with a SIR of
1.4 (P = 0.01). This is in contrast to other studies, which
found higher overall risks ranging from 3.3 to 3.6 [10,
21]. However, these were primarily driven by the high
frequency and particularly elevated risk for skin cancers,
which were excluded from our analysis. As discussed fur-
ther below, it appears that specific subsets of cancers and
patient or transplant characteristics are associated with a
particularly elevated risk for malignancy compared with
the general population.
First, consistent with the pattern observed in the gen-
eral population and as demonstrated in previous reports
[14], it appears that older patients have a greater risk
for developing malignancy after transplantation (RR 6.2
for age ≥60 compared with <40 years). However, it is
noteworthy that the youngest group at the time of trans-
plantation has the highest relative risk compared with
the age-matched general population, with a SIR of 2.3.
This finding has not been addressed extensively in previ-
ous studies, although it is noted on examination of data
presented in some [10, 15]. It is also consistent with the
pattern observed in the very large collaborative study of
cancer risk in chronic dialysis patients [22]. One possible
explanation is that patients transplanted at a younger age
have a longer life expectancy post-transplant, and may
therefore have a particularly increased exposure to the
risks of immunosuppression. Second, younger patients
may not have been exposed to certain viruses until af-
ter transplantation, possibly increasing the risk of virus-
related malignancy. An example of this is post-transplant
lymphoma, which is most likely to occur in patients who
are Epstein-Barr virus–seronegative before transplanta-
tion [23]. In summary, this issue is especially important
because cancer in younger patients may result in a greater
potential of years of life lost, and raises the question of
whether this group requires increased cancer surveillance
post-transplantation.
There is ongoing controversy over the primary mech-
anisms of cancer risk in the setting of immunosuppres-
sion [7]. One hypothesis is that cancers result from
oncogenic viral infections that are no longer kept in check
by the depressed immune system. The data from the
CTTR supports this contention because its main find-
ings primarily demonstrate an increase in those malig-
nancies with a clear association with viral infection, such
as lymphomas, cervical cancer, and Kaposi’s sarcoma [8].
The other proposed mechanism is that of reduced im-
mune surveillance against a variety of nonviral tumor
antigens [24]. Data consistent with this comes from both
the Nordic [20] and Australia/New Zealand [25] renal
transplant registries, which show a more widespread in-
crease in all kinds of malignancies, including the common
solid organ cancers seen in the general population, with
the exception of breast cancer. Our data provides support
for both of these mechanisms. Consistent with findings of
almost all studies examining post-transplant malignancy,
we found an increase in the risk for lymphoma, which is
commonly associated with Epstein-Barr virus infection.
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Table 3. Risk factors for malignancy post renal transplantation: Multivariable analyses
All cancers Excluding nonmelanoma skin cancer
Characteristic RR (95% CI) P value RR (95% CI) P value
Age at first transplant years
<40 – reference 1.0 <0.001 1.0 <0.001
40 to 59 2.9 (1.8, 4.6) 3.6 (1.9, 6.7)
≥60 6.2 (2.8, 13.5) 6.6 (2.5, 17.1)
Race
Caucasian/Other – reference 1.0 0.389 1.0 0.469
African American 0.7 (0.4, 1.3) 1.5 (0.8, 3.0)
Hispanic 0.7 (0.5, 1.3) 1.3 (0.7, 2.5)
Number of transplants
1 – reference 1.0 0.757 1.0 0.350
≥2 1.1 (0.6, 2.0) 1.5 (0.7, 3.2)
Donor source
Living – reference 1.0 0.682 1.0 0.989
Cadaveric 1.1 (0.7, 1.8) 1.1 (0.7, 1.8)
Transplant year
<1984 – reference 1.0 0.800 1.0 0.418
≥1984 1.1 (0.6, 1.8) 1.3 (0.7, 2.7)
Cause of ESRD
DM – reference 1.0 0.471 1.0 0.230
HTN 1.6 (0.8, 3.4) 2.3 (0.9, 6.0)
Glomerulonephritis 1.0 (0.5, 2.3) 1.3 (0.5, 3.8)
Miscellaneous 1.1 (0.6, 2.3) 1.5 (0.6, 4.0)
Table 4. Standardized incidence ratios
Characteristic Cancer patients Na Person-years SIR (95% CI) P value
All cancers 57 1637 9852 1.4 (1.1, 1.8) 0.010
Site of cancer
Breast 4 1637 9959 0.7 (0.5, 0.9) 0.005
Lung 4 1637 9955 0.7 (0.5, 0.9) 0.023
Colorectal 6 1637 9956 1.5 (1.1, 1.9) 0.007
Renal cell 6 1637 9941 7.2 (2.8, 18.7) <0.001
Lymphomas 8 1637 9946 4.9 (2.1, 11.2) <0.001
Age at transplant years
<40 18 864 6076 2.3 (1.7, 3.1) <0.001
40 to 59 32 675 3322 1.3 (0.9, 1.9) 0.103
≥60 7 123 454 0.8 (0.5, 1.2) 0.265
Race
Caucasian 23 831 5163 1.1 (0.8, 1.4) 0.639
African-American 18 354 1941 1.6 (1.2, 2.3) 0.006
Hispanic 5 207 732 2.4 (1.3, 4.5) 0.008
Number of transplants
1 48 1637 8853 1.3 (1.0, 1.6) 0.072
≥2 9 183 1000 2.9 (1.7, 4.9) <0.001
Donor source
Cadaveric 43 1287 6765 1.3 (1.0, 1.8) 0.081
Living 14 427 3087 1.7 (1.1, 2.6) 0.026
Transplant year
<1984 12 365 2836 1.4 (0.9, 2.2) 0.092
≥1984 45 1314 7016 1.4 (1.0, 1.9) 0.050
Duration post-transplant years
≤5 27 1637 5668 1.2 (0.9, 1.6) 0.205
6 to 10 13 834 2588 1.1 (0.5, 2.6) 0.775
>10 17 355 1596 2.4 (1.6, 3.8) <0.001
Cause of ESRD
DM 6 355 1618 0.8 (0.5, 1.3) 0.419
HTN 21 307 1748 1.6 (1.2, 2.3) 0.002
Glomerulonephritis 10 290 2115 1.2 (0.9, 1.7) 0.255
Miscellaneous 20 685 4371 1.5 (0.9, 2.5) 0.099
a102 cases with missing follow-up data were excluded.
Breast and lung cancers, on the other hand, appeared
to have a slightly lower risk compared with the general
population. This finding is consistent with previous stud-
ies [26], including the CTTR. This could occur as a result
of intense medical screening that is part of the evaluation
process before transplantation, leading to the exclusion
of high-risk patients. In contrast to the CTTR, we did
observe an increase in colon cancers consistent with the
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reduced immune surveillance hypothesis. This has also
been demonstrated in previous studies, particularly in
those with long periods of follow-up such as ours [10,
12]. One such study found that the risk for colon cancer
increased only after 10 years post-transplantation [12].
We also observed that the risk for renal cell cancer was
substantially increased, over 7-fold higher than in the gen-
eral population. However, it is unclear whether the risk
for renal cell carcinoma is influenced by immunosuppres-
sion because it is very difficult to control for the known
risk related to a preceding period of uremia. We had no
comparison group of patients on dialysis available to ex-
amine this issue. One study addressing this issue showed
no further increase in risk of renal cancer in transplant
patients compared with those on dialysis [12]. However,
it may still be prudent to strongly consider surveillance
for renal cell cancer with ultrasound or computed tomog-
raphy, as has been suggested previously [6]. In summary,
we have demonstrated an increase in certain cancers with
and without clear viral associations, supporting a role for
both proposed mechanisms for carcinogenesis after trans-
plant immunosuppression.
It is intuitive that an increase in the amount of immuno-
suppression may lead to a greater risk of malignancy.
This has been shown previously with use of more intense
immunosuppressive regimens, correlating with the oc-
currence of post-transplant lymphoma [27] and a longer
duration of immunosuppression, correlating with subse-
quent development of skin cancers [28]. Our data also
support this principle in a number of ways. Both a higher
transplant number and longer duration post-transplant
were very strongly associated with an increased risk of
cancer compared with the general population. In ad-
dition, although limited by power, we were unable to
demonstrate a difference in cancer risk between the two
eras of immunosuppression. Although data is conflict-
ing, other studies have similarly found no difference in
malignancy risk when comparing primarily azathioprine-
versus cyclosporine-based regimens [24, 29, 30]. Over-
all, this strongly suggests that the duration and possibly
total dose of immunosuppression, rather than the type
of immunosuppression, is the most important factor in
the subsequent development of malignancy. Of note, the
incidence of malignancy in our study (skin included) ap-
proaches almost 40% after 25 years of transplantation.
This correlates well with figures ranging from 17% to 50%
at 20 years from various previous studies with long-term
follow-up [10, 14, 29].
No increased risk was detected among racial groups for
patients undergoing transplantation, although the analy-
sis was limited by small numbers. Of potential interest was
that among the racial groups, the risk of cancer compared
with the general population was highest for the trans-
planted Hispanic group, with an SIR of 2.4. Although
this could be a chance finding, it is noteworthy that the
Hispanic general population demonstrates a lower inci-
dence of malignancy compared with Caucasians [31]. A
potential explanation for this is that Hispanics either have
less access to, or are less likely to, seek access to health
care. The issue of access to care may be obviated in trans-
planted patients, which out of necessity receive frequent
medical follow-up, resulting in an exaggerated increase
in cancer incidence in the transplanted Hispanic group
not present in Caucasians when a comparison is made to
the general population.
There are several limitations to this study, most of
which relate to its single-center nature. Even with the long
time span, the total number of cancers was small relative
to much larger registry studies, thus substantially limit-
ing the power to detect weak associations. In addition,
stratification into multiple subgroups increases the risk
of chance findings. We attempted to limit this by employ-
ing a Bonferroni corrected P value in order to provide a
more conservative measure, of which findings were most
likely to be valid. However, we still presented data with
a standard P value of 0.05 as well so as not to dismiss
weaker but potentially important findings. Advantages
of this study include the ability to produce true cancer
risk estimates on the basis of incidence as calculated by
person-years, which are not available from a large registry
such as the CTTR. The utilization of the SIR, which in-
corporates the duration of follow-up available, minimizes
problems with loss to follow-up which can substantially
affect cancer risks based purely on a percentage of cases
of cancer seen, rather than incidence based on person-
years. However, we cannot exclude the possibility that
some patients were lost to follow-up because they died
from malignancy, which would tend to lead to an under-
estimation of the cancer risks we have presented. Finally,
the long period of follow-up available for many patients
allowed estimation of cancer risk in the long-term.
CONCLUSION
This study provides cancer risk estimates after renal
transplantation compared with the U.S. general popula-
tion data available from SEER. Its results emphasize the
need for vigilance after transplantation given the find-
ings of a heightened risk of a variety of malignancies,
particularly affecting the younger age groups, and with a
progressive increase in incidence over the duration of the
transplant. This highlights the need for strategies to limit
the amount of immunosuppression given in the long-term
to prevent the many successes of transplantation being
marred by the risk of malignancy.
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